RMD: Sleep Health Demand And GLP 1 Therapies Will Support Future Upside

Analysts have trimmed their fair value estimate for ResMed by $10 to $260.60. This reflects lower price targets driven by expectations of moderating revenue growth and profit margins, despite ongoing interest in sleep apnea demand trends.

Analyst Commentary

Recent research on ResMed shows a mix of optimism about long term sleep apnea demand trends and caution around potential competitive and earnings risks. Price targets have generally been revised lower, but views on the company’s positioning and execution remain divided.

Bullish Takeaways

Bullish analysts highlight ongoing strength in underlying obstructive sleep apnea and CPAP patient activity, which they see as supportive of ResMed’s core device and mask volumes over time.
There is continued enthusiasm around possible demand growth tied to GLP 1 therapies and consumer wearables, which analysts view as potential drivers of broader diagnosis and treatment rates for sleep apnea.
Some price targets, such as the revised US$266 level, still sit above the trimmed fair value estimate. This suggests that certain bullish analysts see room for further execution or valuation upside if current concerns ease.
JPMorgan’s earlier initiation with a constructive stance, even after later target reductions from others, signals that at least one major global house sees a meaningful long term opportunity for ResMed if it delivers on growth initiatives.

Bearish Takeaways

Bearish analysts have lowered their price targets and, in some cases, ratings, which feeds into the reduced fair value estimate and reflects more cautious assumptions on ResMed’s ability to sustain prior growth trends.
The downgrade to Equal Weight with a reduced US$230 target is tied to expectations of lower revenue growth if Philips re enters the U.S. device market in 2027, which could pressure ResMed’s market share and pricing power.
Multiple cuts to targets in recent months signal broader concern that profit margins and earnings growth may be harder to maintain. This directly weighs on valuation support for the stock.
Some research highlights a more guarded near term earnings outlook, suggesting that even analysts constructive on the medium to longer term opportunity want clearer evidence of execution before assigning higher valuation multiples.

What’s in the News for ResMed

ResMed reported fiscal Q3 2026 results with 11% year on year revenue growth, supported by demand for sleep apnea devices, consumables and software platforms such as AirView, according to recent coverage.
Reports highlight gross margin expansion and operating cash flow above net income, alongside ongoing investments in digital health tools and capital returns via dividends and share buybacks, based on the same Q3 2026 commentary.
ResMed’s stock is reported to be down 26% over six months, with shares recently up more than 4% and trading about 28% to 30% below some intrinsic value estimates that reference GF Score metrics of 90 to 94 out of 100, according to GuruFocus based analysis.
Morgan Stanley downgraded ResMed from Overweight to Equal Weight and cut its price target from US$286 to US$230, citing limited near term profit margin growth, modest earnings expectations and potential competition from Philips’ expected U.S. market re entry by 2027, according to recent broker commentary.
News flow also points to roughly US$3.8 million of insider share sales over the past three months with no reported insider purchases, which some coverage frames as caution on the near term outlook for ResMed.

Valuation Changes for ResMed

Fair Value: trimmed from $270.60 to $260.60, a reduction of about 3.7% in the central valuation anchor for ResMed.
Discount Rate: adjusted slightly from 7.50% to 7.49%, indicating minimal change in the assumed cost of capital used in the model.
Revenue Growth: moderated from 7.67% to 7.21%, reflecting slightly lower expectations for ResMed’s future top line expansion.
Net Profit Margin: moved from 28.67% to 28.16%, a small reduction in the projected level of profitability on future revenues.
Future P/E: eased from 23.93x to 23.75x, suggesting a modestly lower valuation multiple applied to ResMed’s expected earnings.

0 views

Key Takeaways

Strategic acquisitions, innovation, and digital health adoption are broadening market reach, deepening customer retention, and driving resilient revenue and margin growth.
Operational efficiencies and increased awareness in sleep health strengthen competitive advantages, fueling long-term earnings expansion and greater profitability.
Competitive, regulatory, and market shifts threaten ResMed's pricing power, market share, and profitability, especially as its hardware-focused model faces digital disruption and rising compliance costs.

Catalysts

About ResMed

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.What are the underlying business or industry changes driving this perspective?

Strategic investments in expanding the diagnosis and treatment funnel-including acquisitions like VirtuOx, Ectosense, and Somnoware-are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.
Increased global awareness of sleep health issues, amplified by direct-to-consumer marketing campaigns and education programs for primary care physicians, is driving higher diagnosis and treatment rates, translating to elevated demand for ResMed's products and sustained top-line revenue growth.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time.
Ongoing innovation in product development-including new releases of CPAP devices, mask interfaces, and integration of AI-driven features-strengthens ResMed's competitive differentiation and supports premium pricing power, driving both revenue and margin expansion.
Optimization initiatives in procurement, manufacturing, and logistics-along with the build-out of the U.S. manufacturing footprint-are structurally improving gross margins, which, when combined with operating leverage from global scale, are expected to boost overall earnings and free cash flow.

ResMed Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ResMed's revenue will grow by 7.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 27.4% today to 28.2% in 3 years time.
Analysts expect earnings to reach $1.9 billion (and earnings per share of $13.51) by about June 2029, up from $1.5 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.8x on those 2029 earnings, up from 18.9x today. This future PE is lower than the current PE for the AU Medical Equipment industry at 25.0x.
Analysts expect the number of shares outstanding to decline by 0.93% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.49%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The potential resumption or tightening of CMS competitive bidding programs in the US could pressure pricing and reimbursement rates for ResMed's core devices, leading to reduced revenue growth and compressed net margins.
Intensifying competition in the sleep apnea and respiratory market-including from alternative therapies such as GLP-1 drugs and hypoglossal nerve stimulators-may slow device adoption and erode ResMed's market share, negatively impacting topline revenue and margins.
Heavy dependence on positive secular trends (aging population, home-based care, and sleep disorder prevalence) exposes ResMed to risk if healthcare cost containment or stricter reimbursement policies emerge globally, which could limit growth and pressure earnings.
The accelerating transition toward digital and preventative health, as well as commoditization of respiratory medical equipment, may lower average selling prices and challenge ResMed's hardware-centric business model, impacting net margin expansion and longer-term profitability.
Rising regulatory and compliance demands-especially related to data privacy, cybersecurity, and evolving healthcare software oversight-could increase R&D and SG&A costs, pose legal risks, and potentially delay new product launches, putting pressure on future earnings and operating leverage.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $260.6 for ResMed based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $325.0, and the most bearish reporting a price target of just $180.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $6.8 billion, earnings will come to $1.9 billion, and it would be trading on a PE ratio of 23.8x, assuming you use a discount rate of 7.5%.
Given the current share price of $198.6, the analyst price target of $260.6 is 23.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ResMed?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge

RMD: Sleep Health Demand And GLP 1 Therapies Will Support Future Upside